CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-22 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −462,374 | 6,576,523 | ||
| 2025-09-22 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 6,476,523 | ||
| 2025-09-20 | Pulik Richard CFO | Shares withheld for taxes | −2,129 | $15.04 | $32K | 391,849 |
| 2025-09-19 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +1,000,000 | $3.85 | $3.9M | 2,653,585 |
| 2025-09-19 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −683,818 | $14.95 | $10.2M | 1,969,767 |
| 2025-09-19 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000,000 | 7,038,897 | ||
| 2025-09-18 | Gline Matthew CEO | Purchase | +3,315 | $15.07 | $50K | 17,287,081 |
| 2025-09-10 | MANCHESTER KEITH S Director | Grant or award | +14,524 | 1,948,403 | ||
| 2025-09-10 | MANCHESTER KEITH S Director | Grant or award · Stock Option (Right to Buy) | +33,726 | 33,726 | ||
| 2025-09-10 | Gold Daniel Allen Director | Grant or award | +14,524 | 8,971,164 | ||
| 2025-09-10 | Gold Daniel Allen Director | Other disposition | −5,270 | $13.77 | $73K | 8,965,894 |
| 2025-09-10 | Gold Daniel Allen Director | Grant or award · Stock Option (Right to Buy) | +33,726 | 33,726 | ||
| 2025-09-10 | Fitzgerald Meghan Director | Grant or award | +14,524 | 43,900 | ||
| 2025-09-10 | Fitzgerald Meghan Director | Other disposition | −937 | $13.77 | $13K | 42,963 |
| 2025-09-10 | Fitzgerald Meghan Director | Grant or award · Stock Option (Right to Buy) | +33,726 | 33,726 | ||
| 2025-09-10 | Oren Ilan Director | Grant or award | +14,524 | 119,205 | ||
| 2025-09-10 | Oren Ilan Director | Other disposition | −2,043 | $13.77 | $28K | 117,162 |
| 2025-09-10 | Oren Ilan Director | Grant or award · Stock Option (Right to Buy) | +33,726 | 33,726 | ||
| 2025-09-10 | MOMTAZEE JAMES C Director | Grant or award | +14,524 | 111,194 | ||
| 2025-09-10 | MOMTAZEE JAMES C Director | Other disposition | −3,282 | $13.77 | $45K | 107,912 |
Page 19 of 29 · 570 trades